Form 4: Doximity Director Executes Planned Stock Option Exercise and Share Sale

A Doximity, Inc. director exercised stock options and sold 5,000 shares of Class A Common Stock for $60.04 per share on July 11, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Regina M. Benjamin, a Director of Doximity, Inc., engaged in transactions involving the company's stock on July 11, 2025.
• Benjamin exercised a stock option to acquire 5,000 shares of Class B Common Stock at an exercise price of $2.21 per share.
• Concurrently, 5,000 shares of Class B Common Stock were converted into 5,000 shares of Class A Common Stock.
• Following the conversion, 5,000 shares of Class A Common Stock were sold at a price of $60.04 per share.
• These sales were executed automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2025.
• After these reported transactions, Benjamin beneficially owns 16,618 shares of Class A Common Stock directly and holds 366,138 stock options for Class B Common Stock.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction (option exercise and sale under a 10b5-1 plan) and does not inherently indicate positive or negative sentiment about the company's future performance. It's a planned liquidity event for the director.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and transparent approach to insider trading, which helps mitigate concerns about opportunistic trading.
• The exercise of stock options allows the director to realize value from previously granted equity compensation, which is a common and expected part of executive and director compensation.

Negatives

• The sale of 5,000 shares by a director, even if pre-planned, represents a reduction in direct ownership, which some investors might interpret as a lack of confidence, though this is often a routine liquidity event.

Risks

• No specific risks are detailed in this Form 4 beyond the inherent risks of stock ownership and market fluctuations. The document primarily reports a transaction rather than disclosing new risk factors.

Future Outlook

No specific future outlook or guidance is provided in this Form 4, as it primarily reports a scheduled insider transaction.

Industry Context

This Form 4 reports a routine insider transaction for Doximity, Inc., a digital platform for medical professionals. Such transactions, particularly those executed under Rule 10b5-1 plans, are common across all industries as part of executive compensation and personal financial planning, reflecting a standard mechanism for insiders to manage their equity holdings.

Comparison to Industry Standards

• Insider transactions, including option exercises and subsequent sales under Rule 10b5-1 plans, are standard practices for executives and directors in publicly traded companies across all sectors, including healthcare technology.
• The use of a Rule 10b5-1 plan aligns with best practices for corporate governance, providing an affirmative defense against insider trading allegations by pre-scheduling transactions.
• The specific sale price of $60.04 per share is a market-determined value for Doximity's Class A Common Stock at the time of the transaction and is not directly comparable to specific projects or results of other companies without broader market context.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by a director could be viewed as a minor reduction in insider ownership, but the pre-planned nature of the transaction under a Rule 10b5-1 plan mitigates negative interpretations, as it is a common and transparent method for insiders to manage their equity holdings and realize compensation.

Next Steps

• Continued vesting of remaining stock options for Regina M. Benjamin, subject to continuous service with Doximity, Inc.
• Potential future transactions by the Reporting Person under the existing Rule 10b5-1 plan or other arrangements.

Key Dates

Keywords

Doximity, DOCS, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Director Transaction, Class A Common Stock, Class B Common Stock, Equity Compensation